Stock SAN SANOFI
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 11:35:17 2024-05-27 am EDT 		5-day change 1st Jan Change
89.86 EUR +0.38% Intraday chart for Sanofi +0.79% +0.11%
May. 27 Sanofi Gets US FDA’s Priority Review for Expanded Use of Blood Cancer Drug Sarclisa MT
May. 27 Sanofi: FDA grants priority review in myeloma CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 112,310 98,877 111,194 112,665 112,549 112,336 - -
Enterprise Value (EV) 1 128,816 107,666 121,177 119,102 120,342 119,020 114,614 109,963
P/E ratio 40 x 8.01 x 17.8 x 16.7 x 20.8 x 16 x 12.9 x 11.5 x
Yield 3.51% 4.07% 3.76% 3.96% 4.19% 4.32% 4.55% 4.98%
Capitalization / Revenue 3.11 x 2.74 x 2.94 x 2.62 x 2.61 x 2.43 x 2.25 x 2.13 x
EV / Revenue 3.57 x 2.99 x 3.21 x 2.77 x 2.79 x 2.57 x 2.3 x 2.09 x
EV / EBITDA 10.8 x 9.41 x 9.95 x 8.14 x 8.44 x 8.76 x 7.37 x 6.62 x
EV / FCF 21.7 x 15.4 x 15 x 14 x 14.2 x 16.3 x 12.6 x 10.9 x
FCF Yield 4.6% 6.48% 6.68% 7.12% 7.04% 6.15% 7.93% 9.17%
Price to Book 1.9 x 1.57 x 1.62 x 1.5 x 1.52 x 1.47 x 1.4 x 1.32 x
Nbr of stocks (in thousands) 1,253,178 1,256,375 1,255,293 1,254,060 1,253,891 1,250,117 - -
Reference price 2 89.62 78.70 88.58 89.84 89.76 89.52 89.52 89.52
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/1/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 36,126 36,041 37,761 42,997 43,070 46,297 49,844 52,638
EBITDA 1 11,904 11,443 12,183 14,627 14,259 13,579 15,546 16,613
EBIT 1 9,758 9,762 10,714 13,040 12,670 12,250 13,979 15,118
Operating Margin 27.01% 27.09% 28.37% 30.33% 29.42% 26.46% 28.05% 28.72%
Earnings before Tax (EBT) 1 2,822 13,804 7,798 8,268 7,038 8,950 11,884 13,431
Net income 1 2,806 12,314 6,223 6,720 5,400 7,083 8,705 9,665
Net margin 7.77% 34.17% 16.48% 15.63% 12.54% 15.3% 17.47% 18.36%
EPS 2 2.240 9.820 4.970 5.370 4.310 5.590 6.941 7.808
Free Cash Flow 1 5,928 6,982 8,096 8,483 8,478 7,320 9,089 10,085
FCF margin 16.41% 19.37% 21.44% 19.73% 19.68% 15.81% 18.24% 19.16%
FCF Conversion (EBITDA) 49.8% 61.02% 66.45% 58% 59.46% 53.91% 58.47% 60.7%
FCF Conversion (Net income) 211.26% 56.7% 130.1% 126.24% 157% 103.35% 104.41% 104.35%
Dividend per Share 2 3.150 3.200 3.330 3.560 3.760 3.869 4.070 4.457
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/1/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 10,432 9,994 9,674 10,116 12,482 10,725 10,222 9,965 11,964 10,919 10,464 10,464 12,969 11,884 10,805
EBITDA 1 3,952 2,623 3,426 3,163 4,931 3,107 3,703 3,087 4,460 3,009 3,192 2,706 4,328 2,628 -
EBIT 1 3,558 2,256 3,065 2,753 4,498 2,724 3,333 2,726 4,028 2,583 2,843 2,558 4,212 2,825 3,045
Operating Margin 34.11% 22.57% 31.68% 27.21% 36.04% 25.4% 32.61% 27.36% 33.67% 23.66% 27.17% 24.45% 32.48% 23.77% 28.18%
Earnings before Tax (EBT) 1 2,957 1,391 2,349 1,383 2,666 1,921 2,468 1,718 2,971 -249 1,310 1,892 3,789 2,281 -
Net income 1 2,317 1,131 2,009 1,175 2,076 1,460 1,995 1,435 2,525 -555 1,133 1,479 2,824 1,651 -
Net margin 22.21% 11.32% 20.77% 11.62% 16.63% 13.61% 19.52% 14.4% 21.1% -5.08% 10.83% 14.13% 21.77% 13.9% -
EPS 2 1.850 0.9000 1.610 0.9400 1.660 1.160 1.600 1.150 2.010 -0.4400 0.9100 1.178 2.239 1.310 -
Dividend per Share 2 - 3.330 - - - 3.560 - - - 3.760 0.9292 0.9289 0.9289 0.9289 0.9885
Announcement Date 10/28/21 2/4/22 4/28/22 7/28/22 10/28/22 2/3/23 4/27/23 7/28/23 10/27/23 2/1/24 4/25/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 16,506 8,789 9,983 6,437 7,793 6,685 2,279 -
Net Cash position 1 - - - - - - - 2,373
Leverage (Debt/EBITDA) 1.387 x 0.7681 x 0.8194 x 0.4401 x 0.5465 x 0.4923 x 0.1466 x -
Free Cash Flow 1 5,928 6,982 8,096 8,483 8,478 7,320 9,089 10,085
ROE (net income / shareholders' equity) 12.7% 12.1% 12.5% 14.4% 13.6% 12.4% 13.6% 14%
ROA (Net income/ Total Assets) 2.5% 6.47% 5.3% 8.37% 4.27% 6.36% 7.22% 7.45%
Assets 1 112,072 190,442 117,327 80,248 126,517 111,308 120,549 129,648
Book Value Per Share 2 47.20 50.30 54.80 59.70 59.20 60.80 64.20 67.70
Cash Flow per Share 2 6.160 5.940 8.360 8.410 8.200 8.110 9.500 11.00
Capex 1 1,816 1,329 2,043 2,201 3,024 1,991 2,403 2,505
Capex / Sales 5.03% 3.69% 5.41% 5.12% 7.02% 4.3% 4.82% 4.76%
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/1/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sanofi

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.86 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SANOFI Stock Sanofi
+0.11% 121B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.74% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.44% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.97% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. Financials Sanofi